Product
AI AGENTS
INTELLIGENCE SUITE
API, MCP & INTEGRATION
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Patsnap Eureka Platform
IP Search Agents
IP Drafting Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
Materials Agents
SEP Agents
Patsnap Eureka Desktop
BetaAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisProfessional Services
Open Platform
Developer Center
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using Patsnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Sanofi's rilzabrutinib is a reversible BTK inhibitor in Phase III trials for immune thrombocytopenia. Explore late-stage data and the competitive landscape.
Article | Report The zinc-ion battery materials landscape for grid-scale energy storage in 2026: key research directions, patent intelligence gaps, and how to navigate this emerging space.
Article | Report Explore the key engineering tradeoffs between direct and indirect hydrogen storage for mobile fuel cell applications, from compressed gas to LOHC and ammonia cracking.
Article | Report Mapping the 2026 continuous lactate monitor landscape: patent leaders, sensor technologies, clinical applications, and emerging IP white spaces across ICU, sports, and beyond.
Article | Report Amlitelimab's Phase III SOLO program targets drug-free remission in atopic dermatitis — a paradigm shift beyond dupilumab. Explore the OX40L mechanism and competitive landscape.
Article | Report Mapping the 2026 on-orbit satellite servicing patent landscape: engagement systems, debris removal, logistics optimisation, and emerging IP white spaces.
Article | Report SIL vs Performance Level: compare IEC 62061 and ISO 13849 certification frameworks for industrial machine guarding systems. Key differences explained.
Article | Report Tolebrutinib's EMA conditional approval and FDA resubmission in non-relapsing SPMS marks a landmark for CNS-targeted BTK inhibition. What it means for progressive MS.
Article | Report How PIM architecture is dismantling the memory wall: technology clusters, application domains, geographic leaders, and 2026 strategic IP opportunities across 70+ records.
Article | Report Wind turbine blade recyclability is one of renewable energy's most urgent engineering challenges. Explore the key technical barriers, material science gaps, and innovation pathways driving circular blade design.
Article | Report Zola-cel (BMS CD19 CAR-T) in the BREAKFREE trial: autoimmune disease data, mechanism, and competitive landscape vs. KYV-101 by Kyverna Therapeutics.
Article | Report How to build a rigorous SAC patent and literature landscape for hydrogen evolution and CO₂ reduction — data requirements, IPC codes, and search strategy.
Article | Report Map the 2026 transcription factor engineering landscape: zinc fingers, TALEs, gTME, AI-driven design, and emerging nascent RNA-guided approaches. Patent and literature analysis.
Article | Report Explore the core differences between Forward Error Correction and Automatic Repeat Request protocols for reliable industrial wireless communication systems.
Article | Report Deucravacitinib (Sotyktu) expands beyond psoriasis into SLE Phase III trials. Explore TYK2 inhibitor mechanistic rationale, POETYK SLE readouts, and pipeline signals.